Stock Events

Stock Events

Altimmune

M$128

183

+M$0+0% Friday 16:54

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

27.05B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

27MarConfirmed

Q2 2022

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

-0.5

-0.44

-0.38

-0.32

Expected EPS

-0.43

Actual EPS

-0.33

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALT1.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to Altimmune's focus area.

Moderna is involved in mRNA-based vaccines and therapeutics, competing in the same innovative vaccine technology space as Altimmune.

BioNTech competes with Altimmune in the development of vaccines, including their work on COVID-19 vaccines.

Pfizer, through its partnership with BioNTech and other vaccine initiatives, is a major competitor in the vaccine market.

Johnson & Johnson

Johnson & Johnson, with its global reach and vaccine development, competes in the same space as Altimmune.

Inovio Pharmaceuticals

Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine development space.

Dynavax Technologies

Dynavax Technologies specializes in vaccine development, directly competing with Altimmune's vaccine programs.

VBI Vaccines works on developing infectious disease and immuno-oncology vaccines, competing in the same field as Altimmune.

GlaxoSmithKline, with its extensive vaccine portfolio, is a significant competitor in the global vaccine market.

Sanofi is involved in vaccine development and distribution, making it a competitor in the global vaccine and immunotherapy market.

About

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Show more...

CEO

Dr. Vipin K. Garg Ph.D.

Employees

47

Country

United States

ISIN

US02155H2004

WKN

000A2N5Z6

Listings